Open access

Nanoparticle Insulin Drug Delivery — Applications and New Aspects

Written By

Hatice Kübra Elçioğlu and Ali Demir Sezer

Submitted: 25 March 2014 Published: 25 July 2014

DOI: 10.5772/58538

Chapter metrics overview

5,052 Chapter Downloads

View Full Metrics

1. Introduction

Insulin is a hormone secreted from the β cells of the islets of Langerhans, specific groups of cells in the pancreas. Insulin is a protein consisting of two polypeptide chains, one of 21 amino acid residues and the other of 30, joined by two disulfide bridges. It was isolated in 1921 with its first clinical use in 1922 [1]. Insulin is prepared different techniques; One of these isolated from animals and the other is biotechnological preparation using with the recombinant DNA techniques [2, 3].

Insulin is a important player in the control of intermediary metabolism and profound effects on both carbohydrate and lipid metabolism. It has significant influence on protein and mineral metabolism [4, 5].

The traditional and most predictable method for the administration of insulin is by subcutaneous injections. This method is often painful and hence, deterrent to patient compliance especially for those requiring multiple dose injections of four times a day. Also, there have been reports of hypoglycemic episodes following multi dose injections of insulin [6, 7]. Several new approaches to the method have been adopted to decrease the suffering of the diabetic patients including the use of supersonic injector, infusion pump, sharp needles and pens. Some insulin delivery routs so problematic way for example oral administration; Oral delivery eliminates the pain caused by injection, psychological barriers associated with multiple daily injections. Oral delivery of insulin as a non-invasive therapy for Diabetes Mellitus is still a challenge to the drug delivery technology, because insulin is degraded by the enzymes in the acidic environment of stomach. Otherwise insulin delivery via transdermal delivery is so popular way of insulin administration but there are some disadvantages of this route, for example insulin molecular size and application problems etc. While some of them eased the pain encountered by the diabetic patients, they offer incomplete convenience. Even though the ultimate goal would be to eliminate the need to deliver insulin exogenously and regaining the ability of patients to produce and use own insulin, new concepts are currently explored to deliver insulin using oral, pulmonary, nasal, ocular and rectal routes [8, 9].

The success of the route of administration is judged on the basis of its ability to elicit effective and predictable lowering of blood glucose level and therefore minimizing the risk of diabetic complications. It is clear that several difficulties have to overcome with the use of formulation and application devices technology [10, 11]. The various explored routes are reviewed in this chapter. On the other hand, the chapter is an attempt to illustrate the use of insulin drug delivery and their body route in diabetes management benefiting many diabetic patients with promising patient compliance.

Diabetes mellitus (DM) which is a metabolic disorder characterized by chronic hyperglycemia (increased blood and hepatic glucose levels) with disturbances in carbohydrate, fat and protein metabolism, resulted by diminished insulin secretion, impaired insulin action or both. It’s expected to increase from 171 million in 2000 to 366 million by the year 2030 as predicted by the WHO so it continues to increase in prevalence and will become a serious threat of mankind health [12]. Insulin injections remain to be preferred approach for the treatment of insulin-dependent diabetes mellitus (T1DM) and for many patients non-insulin-dependent diabetes mellitus (T2DM) also. People with type 1 diabetes mellitus have an autoimmun mediated destruction of pancreatic islet beta-cells and insulin deficiency. T1DM usually occurs in children and young adults and require daily insulin administration by injection or an insulin pump for survival. On the other hand, insulin resistance (which is associated with excessive glucose production by the liver and impaired glucose utilization by peripheral tissue, especially muscle) is observed in T2DM. They have an impaired endogenous insulin secretion to deal with the increased blood glucose level and majority needs oral antidiabetic drugs. As the disease progresses, the pancreas looses its ability to produce insulin and necessity of insulin therapy increases [12, 13, 14].

Hyperglycemia, recurrence of ample fluctuation of blood glucose levels and insulin resistance can lead to long term complications such as micro and macrovascular. It is well known that improved metabolic control significantly reduces both microvascular (ie, retinopathy, nephropathy and neuropathy) or macrovascular [ie, cardiovascular disease (CVD), cerebrovascular accidents and peripheral vascular disease] complications in diabetes. The development of complications is a cause of considerable morbidity and increases disability and mortality for the individual with diabetes [15].

The conventional pharmacotherapies currently available for the treatment of type-2 diabetes include insulin sensitisers (metformin and thiazolidinediones), insulin secretagogues (sulphonylureas and glinides), alpha-glucosidase inhibitors, insulin and insulin analogues. Glucagon like peptide (GLP)-1 agonists and dipeptidyl peptidase (DPP)-4 inhibitors are the new therapies; that improve glycemic control have recently been developed [16, 17, 18, 19]. These therapies are proposed to treat the key metabolic abnormalities associated with T1DM and T2DM and minimize the side effects noted with conventional therapies. Also in development there are additional therapies that have effects on the kidney to promote glucose excretion [15]. SGLT-2 (proximal renal tubule) has high transport capacity for reabsorption of approximately 90% of primarily filtered glucose. SGLT-2 inhibitors inhibit glucose reabsorption in proximal renal tubule. It results glycosuria leads to a decline in plasma glucose level. A wide variety of SGLT-2 inhibitors are currently under development with Dapagliflozin, Canagliflozin, Empagliflozin being the most advanced substances. Excretion of approximately 40% of primarily filtered glucose translates to a loss of 50–100 g glucose every day. The consequential decline in fasting and postprandial glucose leads to an HbA1c reduction of approximately 0.8%. The loss of energy substrate reduces body weight approximately 3 kg.

Current therapy for diabetes mellitus through oral anti-diabetic drugs and subcutaneous administration of insulin suffers from serious disadvantages, such as patient noncompliance and occasional hypoglycemia. Moreover, these approaches don’t mimic the normal physiological fate of insulin release and doesn’t provide better glucose homeostasis. In normal human physiology when the blood glucose level increases insulin releases from the pancreas, reaches to the hepatic portal vein and goes to liver which is its primary site of action. Subcutaneous administration of insulin moves firstly peripheral tissues and can produce peripheric hyperinsulinemia. In order to overcome the problems associated with parenteral administration of insulin, substantial progress has been made for insulin route such as ocular, vaginal, rectal, oral, pulmonary, transdermal, intranasal, and other routes (Figure 1) [20]. The barriers to reaching the bloodstream are either physical, such as poor absorption at barrier surfaces, or chemical, such as pH inactivation and enzymatic degradation. Delivery of insulin via the ocular route was tested in animal models in combination with different absorption enhancers, with particular attention given to toxicity as polymers were added to overcome low absorption. Vaginal and rectal routes of insulin have also been evaluated but the absorption rate and bioavailability are poor due to the thick mucosal layers in these tissues. Lots of absorption enhancers (bile salts, chelating agents, surfactants, cyclodextrins, and dihydrofusidate) used but they couldn’t prevent local reactions with severe complications.

Figure 1.

The main administration routes for insulin delivery (Reproduced with permission from Ref. [20], Copyright 2013 Elsevier)

Nasal delivery has also been evaluated because of the easy access, high vascularity and large absorption area associated with this route. Unfortunately, highly active mucociliary clearance in the nose hindered prolonged drug action resulting in poor bioavailability. Buccal and sublingual insulin administration provide better results due to the low levels of proteolytic enzyme activity, the high vascularization of the tissue, the large surface area for absorption and the ease of administration. Unlike other delivery routes, the gut is the natural route of nutrient absorption into the circulation. The fact that the gut presents the largest absorption surface of all routes provides better efficacy. However, the multiple layers of oral epithelial cells represent a significant GI barrier to drug penetration, which, coupled with the continuous flow of saliva, leads to poor efficacy.

Taking all of this account oral administration is considered to be the most safest and convenient which delivers the drug directly into the liver through portal circulation, where it inhibits hepatic glucose production. Hence by oral delivery to a greater extent the natural physiological route of insulin can be mimicked (Figure 2) [21]. The highly acidic environment in the stomach and the presence of proteolytic enzymes cause structural instability of the oral delivery of protein and peptide drugs including in the harsh environment of the gastrointestinal system [22, 23, 24]. These drugs should overcome some various GI barriers such as chemical, enzymatic and absorption barriers to obtain adequate bioavailability [25]. Different formulation of polymers for insulin delivery such as liposomes, microspheres, microemulsion and nanoparticles (NPs) have been investigated to circumvent these GI barriers [26, 27].

Figure 2.

Schematic diagrams illustrating the absorption, distribution and elimination of aspart insulin following oral or subcutaneous (s.c.) administration to rats (Reproduced with permission from Ref. [21], Copyright 2013 Elsevier).

Among these approaches nanoparticular sysytems have attracted special interest because of providing the protection to the highly acidic medium in the stomach (preventing enzymatic degradation), prolonging intestinal residence time, increasing the permeability of drugs to systemic circulation (increasing absorption) and providing controlled-release properties for encapsulated drug [12, 28]. For the conventional medicine it is well understood the nanosize along with other characteristics does play an important role as evident from the improved bioavailability/pharmacological availability [29, 30]. Owing to the high surface area to volume ratio of NPs the window of absorption is also high in comparison with microparticles, this is an added advantage in improving the bioavailability of the administered drug [31, 32].


2. Delivery route of insulin

2.1. Oral delivery

Insulin therapy is effectively used in treatment of diabetes mellitus. Insulin is a key player in lowering blood glucose levels for type 1 diabetes and also required at later stages in type 2 diabetes patients. The widely accepted route for delivery of insulin is by parenteral administration but this delivery of insulin usually requires at least three or four daily insulin injections for good glycemic control. Consequently more acceptable different routes of insulin delivery have been searched to decrease suffering from discomfort, local pain, irritation, infection, immune reactions and lipoatrophy at the injection site of insulin. Oral delivery of insulin would deliver the drug directly into the liver through portal circulation and could mimic the physiological fate of endogenously secreted insulin [33, 34, 35]. However polypeptides, like insulin are degraded in the stomach pH and undergo proteolysis by enzymes in the gastrointestinal tract [22, 36]. Moreover the gastrointestinal mucosa has low permeability for large hydrophilic peptides.

In order to overcome the problems associated with parenteral administration of insulin several strategies that are based on nanotechnology has been developed to enhance the intestinal absorption of different protein and peptides. NPs consist of naturally occurring biodegradable polymers are widely investigated in this regard. They have emerged as potential carriers of several therapeutic agents for controlled drug delivery as well as the oral route of insulin. Various natural hydrophilic and hydrophobic polymers used as carrier of oral insulin such as chitosan, alginate, dextran sulphate, etc. are commonly used to prepare NPs.

2.1.1. Polymers used as matrices for oral insulin delivery

Over the past few decades, enhancing attention has been paid to the use of polymeric NPs either hydrophilic or hydrophobic as carriers for insulin delivery. Hydrophilic polymers are of particular interest due to their non-toxic, biocompatible, biodegradable and natural polymers. Among them, chitosan is widely used because of its ease of chemical modification and promising biological properties. Hydrophilic polymers

Chitosan (CS): CS is well known naturally occuring copolymer of beta [1-4] linked and N-acetyl glucosamine and have been generally found in crustacean (crabs, shrimps and lobsters) shell and in some fungi or yeast. It is a biodegradable, biocompatible, non toxic, non-allergic easily absorbable natural hydrophilic polymer properties that have resulted in a wide array of applications in biomedical and drug delivery research [29, 30, 37]. Moreover it prolongs the intestinal residence time that shows its mucoadhesive property [38] (Figure 3). It has also been shown as a paracellular permeability enhancer by interacting with the TJ proteins occluding ZO-1 and opens the tight junctions between epithelial cells [34, 39, 40]. In addition to these properties it increases the stability of nanospheres and faciliates effective encapsulation of proteins and drugs that make it as a suitable carrier material [38, 41, 42]. CS have been extensively used to develope new chitosan derivatized polymers. CS combined with poly(γ-glutamic acid) (γ-PGA) based insulin NPs are used as hydrophilic polymers for oral insulin delivery. In vivo preclinical studies of this formulations at a dose of 30 IU/kg in streptozotocin (STZ) induced diabetic rat models showed increased intestinal absorption of insulin from γ-PGA NPs. It has got long lasting hypoglycemic effect and 15% relative bioavailability compared to subcutaneous (sc) injection [43]. The same formulation filled in enteric coated capsules was even better at the same dose, showing 20% oral bioavailability. Also aspart insulin (=monomeric, 3 times faster than regular) is encapsulated in the same CS-γ-PGA; has got 15.7 % oral bioavailability [21, 44].

Moreover insulin loaded NPs with carboxylated chitosan and Poly-methyl methacrylate (PMMA) were developed to improve the insulin delivery via oral route. One of the most widely investigated polymer towards peptide delivery is acrylates which have high interest because of its pH sensitivity and carboxyl groups to enhance the bioadhesivity, alter the tight junction, chelate the Ca2+ there by inhibiting the proteolytic activity of proteases, etc. They evaluated their ability to reduce blood glucose levels in diabetic rats. In vivo experiments resulted in the reduction of blood glucose levels by 67% at a dose of 100 IU/kg and the pharmacological bioavailability of the 25 IU/kg at a dose of PMMA NPs was 9.7% [45, 46].

Chitosan with sodium alginate is being prepared another insulin loaded nanoparticle product which is used to improve the loading capacity and activity maintenance. It’s observed that when insulin-loaded nanospheres (25, 50, 100 IU/kg) administered orally to diabetic rats they reduced glycaemia in a dose dependent manner. Their pharmacological availabilities are found 7.1, 6.8 and 3.4 %, respectively [33, 47, 48].

Figure 3.

In-vivo efficiency of orally delivered insulin and chitosan/insulin self-assembled NPs (Reproduced with permission from Ref. [38], Copyright 2013 Elsevier).

In addition hydroxypropyl methylcellulose phthalate (HPMCP) is a pH-sensitive polymer designed as an enteric coating material. It reduces the release of drug in acidic conditions and also to improve the colloidal stability of the particles. The release of insulin from CS/HPMCP NPs were significantly reduced at acidic pH and even after 6 h it was less about 25% only. Insulin was protected from enzymatic degradation in the case of CS/HPMCP in comparison with native chitosan particles. Insulin loaded chitosan and HPMCP NPs were orally administered to diabetic wistar rats. The pharmacological availability was 3.02% and 8.47%, respectively, for the chitosan and the modified NPs. In comparison to oral insulin solution the hypoglycaemic effect was increased by 2.8 and 9.8-folds for the chitosan and the modified NPs, respectively [49, 50, 51].

Dextran sulphate-vitamin B12: Dextran sulphate is a non-toxic and highly water soluble different polymer used as matrices for oral delivery of insulin. Vitamin-B12 demonstrated as a ligand to enhance the uptake of the dextran NPs and their translocation across the gastrointestinal tract for high bioavailability. Insulin conjugated to dextran-vitamin B12 NPs to diabetic rats that had the least amount of cross linking were found to be most effective at lowering blood glucose levels (70-75%) in STZ induced diabetic rats. In addition the hypoglycemic effect lasted for 54 h. This modification showed the greatest hypoglycemic effect with a pharmacological availability of 29.4% (Table 1) [49, 52, 53].

Particle Size (nm) Dose (IU/kg) Pharmacological Activity (PA %) Reference
CS-γPGA 218 30 15.1 21, 43, 44
Entericcoated(EC) 233 30 20.1
Aspart Insulin 245 30 15.7
CS-PMMA-PEG 1000 50 1.8 45
CS-PMMA 200-300 25 9.7 46
CS-NP 25-400 7, 14, 21 14, 15.6, 15.3 54
CS-dextran sulfate 500 50, 100 5.6, 3.4 55
CS/HPMCP 255 12.5 8.47 56
CS-Na alginate 748 25, 50, 100 7.1, 6.8, 3.4 57
B12vitamin-dextran 192 20 29.4, 26.5 52, 53

Table 1.

Hydrophilic Polymers. Hydrophobic polymers

Poly (lactide-co-glycolide) (PLGA): Particles consisting of PLGA have been widely studied as therapeutic delivery vehicles owing to their biodegradabile and biocompatibile particles. The hydrophobic nature of PLGA matrices generally makes them incapable of entrapping water-soluble insulin. Intragastric administration of the insulin-loaded PLGA NPs (20 IU/kg) to diabetic rats reduced fasting plasma glucose levels to 57.4% within the first 8h of administration. The relative bioavailability of insulin following oral administration of NPs was 7.7% compared to subcutaneous injection of its solution. Star-branched PLGA (β-cyclodextrin-PLGA) NPs are highly promising for mitigating the burst effect and prolonging the release of insulin. Another study attempted to prevent the burst release of insulin in the stomach by using a cellulose derivative (hydroxypropyl methylcellulose phthalate, HPMCP) to prepare PLGA NPs. This modification reduced the initial release of PLGA NPs in simulated gastric fluid from 50% to 20%, and their relative bioavailability in diabetic rats was approximately 6.2% [49, 58, 59].

Poly lactide acide (PLA): PLA exhibit a strong affinity toward the small intestine due to their polyethylene oxide (PEO) blocks and a high permeation capability toward the cell membrane owing to their amphiphilic property. When orally treated with vesicular PLA NPs loaded with insulin to diabetic mice (50 IU/kg), the highest blood glucose reduction was achieved at 4.5 h. Although this effect lasted at least an additional 18.5 h, increasing the insulin concentration to 100 IU/kg did not enhance this hypoglycemic effect (hypoglycemic effect lasted for 23 hr) [60].

Poly-ε-caprolactone (PCL): NPs prepared with PCL and a monomeric form of insulin analog (aspart-insulin). Their results demonstrated that this formulation allows for preservation of biological activities of insulin, increase of serum insulin levels and improvement of the glycemic response. The maximum effect of reduction in hyperglycemia was found at 8 h after oral administration, which was more pronounced with aspart-insulin-loaded NPs (52%) at the dose of 50 IU/kg [61].

Lipidic polymers [Solid lipid NPs (SLN)]: Previous studies have demonstrated that nanoencapsulation of proteins in SLNs prolongs their blood residence time, modifies their biodistribution and improves their bioavailability [32]. Oral insulin delivery with SLNs administered to diabetic rats, their relative pharmacological bioavailability was 5.1% in comparison to SC injection of insulin; a considerable hypoglycemic effect was also observed during 24 h. To facilitate the transport of particles across the cellular barriers, in an another study the relative bioavailability increased to 7.1%. That study also suggested that increasing the drug entrapment efficiency and utilizing protease inhibitors in SLNs may further enhance the bioavailability of insulin (Table 2).

Particle Size (nm) Dose (IU/kg) BA (relative bioavailability)% Reference
PLGA 150 20 40 7.7 46
PLGA-HPMCP 169 20 60 6.27 59
PLA 50 Hypoglycemic effect lasted for 23 h 60
PCL, Aspart insulin loaded 700 50 52/ 12-24 hr 61

Table 2.

Hydrophobic Polymers.

2.2. Nasal delivery

Nasal administration has attracted a lot of interest as a highly efficient route for the systemic delivery of insulin. It has been well known that the pharmacokinetic profile of intranasal insulin resembles the pulsatile pattern of endogenous insulin secretion in healthy volunteers during meal times [62]. In addition it’s considered as a promising route for the following reasons: the nose has relatively large surface area [150 cm2] of absorption because of numerous microvilli, high vascularized subepithelial layer that passes directly into the systemic circulation, thereby avoiding the loss of drug by first pass metabolism in the liver, high permeability of the nasal epithelial membrane and lower enzymatic activity than the gastrointestinal tract. Although nasal administration of insulin has many advantages, there are also some barriers that limit the intranasal absorption of insulin. Macociliary clearance of formulations from the nasal cavity, low permeability of nasal mucosa to large molecules and the low bioavailability of insulin act as barriers to intranasal absorption. To overcome the various barriers by the nasal route, researchers have studied many extensive range of enhancers such as bile salts and derivatives, sodium lauryl sulfate, laureth-9, phospholipids, cyclodextrins, chitosan and enzyme inhibitors.

At first CS NPs is seemed to be the safest and most effective as a carrier for the nasal delivery of insulin. It protected insulin from degradation in the nasal cavity and increased intranasal absorption of insulin with its positive charge [20, 63]. Also PEG-grafted(g) have been used to enhance the solubility and improve the biocompatibility of CS. Insulin PEG-g with CS NPs administered intranasally to transport insulin across the nasal mucosa in rabbits [64]. However recent studies showed that insulin-CS solution formulation was more effective than the intranasal NP complex (Bioavailability 17 %, 3.6 % respectively) [65]. Because of NPs couldn’t enhance the uptake of insulin; PEGylated trimethyl CS NP results was also not found significantly different from the insulin-CS solution formulation. Besides chitosan reduced gold NPs could enhance insulin transport into cells effectively. After insulin loaded gold Nps administered to diabetic rats by intranasally blood glucose concentration was decreased by 20.27 % [66]. Moreover intranasal route of insulin loaded starch NPs containing sodium glycocholate which’s used as mucoadhesive carrier, caused 70 % reduction of plasma glucose levels and significant hypoglycemia untill 6h in the STZ induced diabetic rats [67].

2.3. Pulmonary delivery

Pulmonary administration is one of the most promising alternative route of insulin delivery. The lungs offer a large and highly vascularised surface area for drug absorption approximately 80-140 m2. Alveoles are covered by a very thin (0.1-0.2 mm) monolayer epithelium, that permits rapid drug absorption. The alveoli can be effectively targeted for drug absorption by drug delivery as an aerosol with a mass median aerodynamic diameter of less than 5µm. First pass metabolism in this administration avoids gastrointestinal system metabolism. Although metabolic enzymes are found in the lungs, their activities and pathways may be different from those found in the GIT and this makes the pulmonary route of many therapeutic proteins and peptides very promising [68, 69, 70].

There are variety of inhalation devices such as metered-dose inhalers or drug powder inhalers. Such as AERx®. Insulin Diabetes Management system developed by Novo Nordisk which delivers aerosol of human insulin; Exubera® developed by Nektar/Pfizer which uses a dry powder formulation. [36].

Dry powder inhalers are currently the most commonly used devices because of their stability and sterility to develope pulmonary insulin. The surfactants, bile salts and fatty acids have been evaluated as absorption enhancers which increase the permeability of drugs through the epithelial membranes. However polyoxyethylene (PE) oleyl ether showed good enhancement sorbitan trioleate exhibited moderate enhancing ability. The enhancing effects of glycerol trioleate, ethyl oleate, oleyl alcohol, palmitic acid and stearic acid were very low. In contrast liposomes are very effective pulmonary absorption enhancers for peptide and protein drugs. They’ve biogenic phospholipids and biocompatible, biodegradable and non immunogenic natural properties.

Experimental studies investigated that insulin could be efficiently encapsulated in liposomes which has approximately 1µm particle size. Liposome mediated pulmonary drug causes enhancement in drug retention time in the lungs and decreases side effects which results increased therapeutic effects. When aerolized insulin liposomes delivered by the inhalation route in mice caused significantly reduction in plasma glucose concentrations [71]. Insulin-calcium phosphate (CAP) and polyethylene glycol (PEG) particles were administered to the lungs by a route of administration of respiratory tract and these particles positively affected the disposition of the insulin in the lungs of rats [72]. Poly-lactide-co-glycolide (PLGA) particles have used to improve insulin loaded particles which has a mean diameter of 400 nm. After the pulmonary administration of insulin with PLGA nanospheres, blood glucose levels were significantly decreased and has got prolonged hypoglycemic response over 48 h in guinea pigs [73]. In another related study poly butyl cyanoacrylate NPs have been used given by pulmonary inhalation of insulin in the lungs resulted stable and prolonged pharmacological effect. A significant reduction in glucose levels were found and the relative pharmacological bioavailability was 57.2 % [70]. Besides insulin/1, 2 dipalmitoyl phosphatidylcholine (DPPC) physical mixture used to enhance insulin absorption in pulmonary route of inhalation. This mixture caused higher blood glucose decrease because of their potentially effective, non-toxic and natural absorption enhancer property [74].

2.4. Buccal delivery

Insulin delivered by buccal route is through an aerosol spray into the oral cavity. It’s absorbed through the inside of the cheeks and in the back of the mouth. The buccal mucosa is excellently accessible with surface area approximately 100-200 cm2, lower risk to be traumatized and a relatively good permeability and perfusion [36, 75, 76, 77]. Several formulations and factors alone or in combination can influence release properties of buccal insulin delivery system. These formulations should contain absorption enhancers (such as surfactants, bile salts, chelators, sodium lauryl sulfate or fatty acids) to increase membrane permeability, enzyme inhibitors to protect the drug from degradation, protease inhibitors (aprotinin and sodium glycocholate) to function drug permeation across mucosa, lipophilicity modifications (conjugation with polymers) bioadhesive delivery systems (gels, films, patchs) and liposomal formulations [36, 76, 78]. Lysalbinic acid which is applied as an absorption enhancer was shown to enhance significantly buccal mucosa permeability for insulin. They investigated that it’s a product of the alkaline hydrolysis of egg albumin and has no irritating or sensibilizing effect upon buccal use. Co-administration of lysalbinic acid and relatively small proteins such as insulin can increase insulin’s permeability from the cheek mucosa of hamster [79].

In the last years a new innovative system has been developed by Generex Biotechnology Corporation (Toronto, Canada). It’s based on a liquid formulation (Oral-Lyn®) of recombinant human insulin, absorption enhancers (which encapsulate and protect the Insulin molecules) and Rapid Mist® device (advanced buccal drug delivery technology). This device sends fastly small particles from an aqueous spray into the oral cavity. This allows rapid insulin absorption.

Oral-Lyn® has been evaluated in healthy persons and type I diabetes. It appears in the circulation within 10 min, the time to peak insulin concentration is is around 25 min. It has observed a more fast onset of action and less prolonged hypoglycemic action. Several studies in patients both type 1 and 2 diabetes demonstrated that this oral insulin can be efficient in controlling postprandial glucose levels. This new buccal insuin system needs further investigations in diabetic patients [35, 36, 76, 78].

2.5. Transdermal delivery

Transdermal insulin delivery is an appealing alternative to the invasive parenteral route of administration and other alternative routes of insulin such as pulmonary and nasal routes because the skin offers the advantages of an easy access and a very large surface area (1-2 m2). It improves patient compliance and avoids both liver’s first pass metabolism and degradation of drugs in gastrointestinal tract. The skin also represents an important painless interface for systemic drug administration. Despite these advantages the human skin limits permeation of foreign compounds especially large hydrophilic molecules like insulin. The stratum corneum; which is the upper layer causes impermeability of the skin by its lipid-rich matrix. Several attemps have been made to overcome the skin barrier and to allow the transfer of large drugs such as insulin. They can be divided into chemical (liposome and chemical enhancers) and physical methods (mainly iontophoresis and sonophoresis).

2.5.1. Transdermal delivery methods

Chemical enhancers such as surfactants, fatty acids, fatty esters and azone-like compounds alter the lipid structure of the stratum corneum. They reduce its barrier properties and enhance its permeability for large molecule drugs that would not pass through the skin.

Iontophoresis is a non invasive technique used to increase transdermal insulin penetration through the skin by the application of a small electric current potential. Large drug molecules can be delivered in a shorter time with the help of this method and it increases drug’s mobility.

Another non invasive technique sonophoresis (ultrasound, phonophoresis) which has been used to enhance (and or or delivery and activity of drugs) skin permeability to various low and high molecules weight drugs such as inulin. Low frequency ultrasound (20-160 kHz) decreases blood glucose levels both in animal and human studies [36, 72, 75].

Microneedles are minimally invasive painless and promising technology to deliver drugs into the skin without disruption of nerve endings. This technology create micronsized channels which interstitial fluid fills up the channels in the skin. It makes hydrophilic transport pathway, faciliates the stratum corneum barrier and increases skin permeability to large molecules [35, 36, 62, 75].

Also other methods have been investigated like microdermabrasion, pressure waves and electroporation but they’re still in at a preliminary stage. Altogether chemical and physical methods they all need further investigations.

2.6. Ocular delivery

Ocular delivery is another the most promising and challenging delivery of ophthalmologically active peptides and proteins for the treatment of ocular diseases. The advantages of the ocular delivery are; less development of immunological reactions in eye tissues, less side effects, no tolerance and avoidance of hepatic first pass metabolism. While the enhancers such as saponin, dodecylmaltoside, tetradecylmaltoside, fusidic acid and glycocholate increases the systemic absorption of insulin in animals they may also increase the eye toxicity [36, 80, 81]. A series of alkylglycosides including tetradecyl-, tridecyl-and dodecylmaltoside and dodecylsucrose were potent stimulators of insulin absorption after topical ocular delivery in anesthetized rats when used at concentrations as low as 0.125 %. These are the most hydrophobic alkylglycoside reagents and were the most effective at enhancing systemic insulin absorption [82]. Moreover sucrose cocoate, a pharmacological excipient of cosmetic and dermatologic preparation was used to determine its possible absorption enhancer in ocular drug delivery. When insulin was delivered ocularly in the presence of 0.5 % sucrose cocoate, plasma insulin levels were significantly enhanced and blood glucose levels were reduced [83]. Because of this observation insulin-containing liposome was prepared to prolong the retention time of the formulation in the precorneal area [84]. This positively charged formulation decreased the blood glucose levels 65-70%.

More recently Gelfoam® an absorbable gelatin sponge ocular devices have been developed as insulin carriers for systemic administration of insulin. Although Gelfoam® containing 0.2 mg insulin has been showed prolonged systemic absorption of insulin within the desired therapeutic levels it may also cause long term toxicity such as slowing the tear production. Because of this toxicity sodium insulin and zinc insulin Gelfoam ocular devices have been developed and these devices were sufficient to control blood glucose levels (60 % of initial) for over 8 hours [62].

2.7. Vaginal delivery

In recent years numerous studies prove that vagina has got rich blood supply and large surface area that means good permeability and can be a potential route for systemic delivery to a wide range of compounds. The main advantages of vaginal drug route are avoidance of first pass metabolism, ease of administration and good permeability for low molecular weight drugs. For systemic delivery bile salts, dihydrofusidate, cyclodextrins, surfactants and chelating agents have been tested as enhancers to facilitate the rate of vaginal absorption but sometimes they induced several local reactions [36, 75].

2.8. Rectal delivery

Rectal route of delivery have been tested soon after the discovery of insulin but several investigators have met absorption problems through the mucosa. This administration’s promising advantage is the possibility of avoiding, to some extent, the hepatic first-pass metabolism. Absorption promoters and surfactants were used to provide highest hypoglycemic effect in rectal insulin delivery. The most effective rectal absorption enhancer polyoxyethylene-9-lauryl ether (POELE) or sodium salicylate were used in insulin suppositories on diabetic dogs. It was investigated that hypoglycemic effect can be achieved about 50-55 % [85].


3. Conclusion

Over the last years numerous studies summerised polymeric NPs focused on different routes of insulin delivery. The association of insulin with NP formulations designed to protect insulin from degradation and enhance its uptake in the ileum. However, more research in this area is needed to achieve the goal that has plagued researchers for many decades. At any rate, polymeric NPs for routes of insulin delivery seems to be the better alternative compared to others.


  1. 1. Rosenfeld L. Insulin: Discovery and controversy. Clinical Chemistry (48):2270-88, 2002.
  2. 2. Verge D. Biotechnological and administration innovations in insulin therapy. Médecine sciences (Paris) (20):986-98, 2004.
  3. 3. Walsh G. Therapeutic insulins and their large-scale manufacture. Applied Microbiology and Biotechnology (67):151-9, 2005.
  4. 4. Saltiel AR, Khan CR. Insulin signaling and regulation of glucose and lipid metabolism. Nature (414):799-806, 2001.
  5. 5. Rotte M, Baerecke C, Pottag G, Klose S, Kanneberg E, Heinze HJ, et al. Insulin affects the neuronal response in the medial temporal lobe in humans. Neuroendocrinology. (81):49-55, 2005.
  6. 6. Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx® insulin diabetes management system: A 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care. (27):162-7, 2004.
  7. 7. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clinical Therapeutics (27):1113-25, 2005.
  8. 8. Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx® insulin diabetes management system: A 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care. (27):162-7, 2004.
  9. 9. Alemzadeh R, Palma-Sisto P, Parton EA, Holzum MK. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes. Diabetes technology & therapeutics (7):587-96, 2005.
  10. 10. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care. (27):1047-53, 2004.
  11. 11. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetic Medicine (20):886-98, 2003.
  12. 12. Krol S., Ellis-Behnke R., Marchetti P., Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments, Nanomedicine: Nanotechnology, Biology, and Medicine, (8):S69-S76, 2012.
  13. 13. Sonia T.A., Sharma C.P., An overview of natural polymers for oral insulin delivery, Drug Discovery Today17(13/14):784-792, 2012.
  14. 14. Golden SH., Sapir T., Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review, Journal of Managed Care Pharmacy, 18(6):S3-S17, 2012.
  15. 15. Cefalu W.T., Evolving treatment strategies fort he management of type 2 diabetes, The American Journal of the Medical sciences, 343(1):21-26, 2012.
  16. 16. Jain S., Saraf S., Influence of processing variables and in vitro characterization of glipizide loaded biodegradable NPs, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, (3):113-117, 2009.
  17. 17. Russel-Jones D., The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes, International Journal of Clinical Practice 64(10):1402-1414, 2010.
  18. 18. Jean M., Alameh M., De Jesus D., Thibault M., Lavertu M., Darras V., Nelea M., Buschmann MD., Merzouki A., Chitosan-based therapeutic NPs for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes, European Journal of Pharmaceutical Sciences, (45):138-149, 2012.
  19. 19. Rekha MR., Sharma CP., Oral delivery of therapeutic protein/peptide for diabetes-Future perspectives, International Journal of Pharmaceutics, (440):48-62, 2013.
  20. 20. Duan X., Mao S., New Strategies to improve the intranasal absorption of insulin, Drug Discovery Today, 15(11/12):416-427, 2010.
  21. 21. Sonaje K., Lin KJ., Wey SP., Lin CK., Yeh TH., Nguyen HN., Hsu CW., Yen TC., Juang JH., Sung HW., Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive NPs vs. subcutaneous injection, Biomaterials, (31):6849-6858, 2010.
  22. 22. Pickup JC., Zhi ZL., Khan F., Saxl T., Birch DJS., Nanomedicine and its potential in diabetes research and practice, Diabetes/Metabolism Research and Reviews (24):604-610, 2008.
  23. 23. Chaturverdi K., Ganguly K., Nadagouda MN., Aminabhavi TM., Polymeric hydrogels for oral insulin delivery, Journal of Controlled Release, (165):129-138, 2013.
  24. 24. Chen M.C., Sonaje K., Chen K.J., Sung H.W.: A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials, 32:9826-9838, 2011.
  25. 25. Maroni A., Zema L., Del Curto MD., Foppoli A., Gazzaniga A., Oral colon delivery of insulin with aid of functional adjuvants, Advanced Drug Delivery Reviews, (64):540-556, 2012.
  26. 26. Packhaeuser CB., Kissel T., On the design of in situ forming biodegrable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) NPs, Journal of Controlled Release, (123):131-140, 2007.
  27. 27. Elsayed A., Remawi MA., Qinna N., Farouk A., Badwan A., Formulation and characterization of an oily-based system for oral delivery of insulin, European Journal of Pharmaceutics and Biopharmaceutics, (73):269-279, 2009.
  28. 28. Durazo SA., Kompella UB., Functionalized nanosystems for targeted mitochondrial delivery, Mitechondrion, (12):190-201, 2011.
  29. 29. Avadi MR., Sadeghi AMM., Mohammadpour N., Abedin S., Atyabi F., Dinarvand R., Rafiee-Tehrani M., Preparation and characterization of insulin NPs using chitosan and Arabic gum with ionic gelation method, Nanomedicine: Nanotechnology, Biology, and Medicine, (6):58-63, 2010.
  30. 30. Sung HW., Sonaje K., Liao ZX., Hsu LW., Chuang EY., pH-Responsive NPs Shelled with Chitosan for Oral Delivery of Insulin: From Mechanism to Therapeutic Applications, Accounts of Chemical Research, 45(4):619-629, 2012.
  31. 31. Gupta AS., Nanomedicine approaches in vascular disease: a review, Nanomedicine: Nanotechnology, Biology, and Medicine, (7):763-779, 2011.
  32. 32. Liu J., Gong T., Wang C., Zhong Z., Zhang Z., Solid lipid NPs loaded with insulin by sodium cholate-phosphatidylcholine –based mixed micelles: Preparation and characterization, International Journal of Pharmaceutics, (340):153-162, 2007.
  33. 33. Woitiski CB., Neufeld RJ., Veiga F., Carvalho RA., Figueiredo IV., Pharmacological effect of orally delivered insulin facilitated b multilayered stable NPs, European Journal of Pharmaceutical Sciences, (41):556-563, 2010.
  34. 34. Woitiski CB., Sarmento B., Carvalho RA., Neufeld RJ., Veiga F., Facilitated nanoscale delivery of insulin across intestinal membrane models, International Journal of Pharmaceutics, (412):123-131, 2011.
  35. 35. Yaturu S., Insulin therapies: Current and future trends at dawn, World Journal of Diabetes, 4(1):1-7, 2013.
  36. 36. Lassmann-Vague V., Raccah D., Alternatives routes of insulin delivery, Diabetes & Metabolism, (32):513-522, 2006.
  37. 37. Bayat A., Dorkoosh FA., Dehpour AR., Moezi L., Larijani B., Junginger HE., Rafiee-Tehrani M., NPs of quaternized chitosan derivatives as a carrier for colon delivery of insulin: Ex vivo and in vivo studies, International Journal of Pharmaceutics, (356):259-266, 2008.
  38. 38. Mukhopadhyay P., Sarkar K., Chakraborty M., Bhattacharya S., Mishra R., Kundu PP., Oral insulin delivery by self-assembled chitosan NPs: In vitro and in vivo studies in diabetic animal model, Materials Science and Engineering C, (33):376-382, 2013.
  39. 39. Jintapattanakit A., Junyaprasert VB., Mao S., Sitterberg J., Bakowsky U., Kissel T., Peroral delivery of insulin using chitosan derivatives: A comparative study of polyelectrolyte nanocomplexes and NPs, International Journal of Pharmaceutics, (342):240-249, 2007.
  40. 40. Ma Z., Lim TM., Lim LY., Pharmacological activity of peroral chitosan-insulin NPs in diabetic rats, International Journal of Pharmaceutics, (293):271-280, 2005.
  41. 41. Mukhopadhyay P., Mishra R., Rana D., Kundu P.P., Strategies for effective oral insulin delivery with modified chitosan NPs, Progress in Poymer Science, (37):1457-1475, 2012.
  42. 42. Jin Y., Song Y., Zhu X., Zhou D., Chen C., Zhang Z., Huang Y., Goblet cell-targeting NPs for oral insulin delivery and the influence of mucus on insulin transport, Biomaterials, (33):1573-1582, 2012.
  43. 43. Sonaje K., Lin YH., Juang JH., Wey Sp., Chen CT., Sung HW., In vivo evaluation of safety and efficacy of self-assembled NPs for oral insulin delivery, Biomaterials, (30):2329-2339, 2009.
  44. 44. Sonaje K., Chen YJ., Chen HL., Wey SP., Juang JH., Nguyen HN., Hsu CW., Lin KJ., Sung HW., Enteric-coated capsules filled with freeze-dried chitosan/poly(γ-glutamic acid)NPs for oral insulin delivery, Biomaterials, (31):3384-3394, 2010.
  45. 45. Sajeesh, S, Vauthier C., Gueutin C., Ponchel G., Sharma C.P., 2010. Thiol functionalised polymethacyrlic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomater. (6):3072-3080, 2010..
  46. 46. Cui F., Qian F., Zhao Z., Yin L., Tang C., Yin C., Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) NPs, Biomacromolecules, (10):1253-1258, 2009.
  47. 47. Woitiski CB., Veiga F., Ribeiro A., Neufeld R., Design for optimization of NPs integrating biomaterials for orally dosed insulin, European Journal of Pharmaceutics and Biopharmaceutics, (73):25-33, 2009.
  48. 48. Sarmento B., Riberio A., Veiga F., Ferreira D., Development and characterization of new insulin containing polysaccharide NPs, Colloids and Surfaces, (53):193-202, 2006.
  49. 49. Card JW., magnuson BA., A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems, American Journal of Physiology – Gastrointestinal and Liver Physiology, (301):G956-G967, 2011.
  50. 50. Li MG., Lu WL., Wang JC., Zhang X., Wang XQ., Zheng AP., Zhang Q., Distribution, transition, adhesion and release of insulin loaded NPs in the gut of rats, International Journal of Pharmaceutics, (329):182-191, 2007.
  51. 51. Jin HE., Xia F., Zhao YP., Preparation of hydroxypropyl methyl cellulose phthalate NPs with mixed solvent using supercritical antisolvent process and its application in co-precipitation of insulin, Advanced Powder Technology, (23):157-163, 2012.
  52. 52. Chalasani KB., Russell-Jones GJ., Jain AK., Diwan PV., Jain SK., Effective oral delivery of insulin in animal models using vitamin B12-coated dextran NPs, Journal of Controlled Release, (112):141-150, 2007.
  53. 53. Chalasani KB., Russell-Jones GJ., Yandrapu SK., Diwan PV., Jain SK., A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin, Journal of Controlled Release, (117):421-429, 2007.
  54. 54. Pan Y., Li YJ., Zhao HY., Zheng JM., Xu H., Wei G., Hao JS., Cui FD., Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. International Journal of Pharmaceutics (249):139-147, 2002.
  55. 55. Sarmento B., Ribeiro A., Veiga F., Ferreira D., Neufelt R., Oral bioavailability of insulin contained in polysaccharide nanoparticles, Biomacromolecules, 8(10): 3054-60, 2007.
  56. 56. Makhlof A., Tozukaa Y., Takeuchia H., Design end evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur. J. Pharm. Sci.42, 445-451, 2011.
  57. 57. Sarmento B., Riberio A., Veiga F, Sampaio P., Neufeld R., Ferreira D. Alginate/chitosan nanoparticles are are effective for oral insulin delivery. Pharmaceutical Research, (24):2198-206, 2007.
  58. 58. Wu ZM., Zhou L., Guo XD., Jiang W., Ling L., Qian Y., Luo KQ., Zhang LJ., HP55-coated capsule containing PLGA/RS NPs for oral delivery of insulin, International Journal of Pharmaceutics, (425):1-8, 2012.
  59. 59. Cui FD., Tao AJ., Cun DM., Zhang LQ., Shi K., Preparation of insulin loaded PLGA-HP55 NPs for oral delivery, Journal of Pharmaceutical Sciences, (96):421-427, 2007.
  60. 60. Xiong XY, Li YP, Li ZL, Zhou CL, Tam KC, Liu ZY et al., Vesicles from pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. Jornal of Control Release (120):11-7, 2007.
  61. 61. Damge C., Maincent P., Ubrich N., Oral delivery of insulin associated to polymeric NPs in diabetic rats, Journal of Controlled Release, (117):163-170, 2007.
  62. 62. Khafagy ES., Morishita M., Onuki Y., Tkayama K., Current Challenges in non-invasive insulin delivery systems: A comparative review, Advanced Drug Delivery Reviews, (59):1521-1546, 2007.
  63. 63. Ferna´ndez-Urrusuno, R. et al. (1999) Enhancement of nasal absorption of insulin using chitosan NPs. Pharm. Res. 16, 1576–1581 (Duan X, 82)
  64. 64. Zhang, X. et al. (2008) Nasal absorption enhancement of insulin using PEG-grafted chitosan NPs. European Journal of Pharmaceutics and Biopharmaceutics (68):526-534, 2008.
  65. 65. Dyer, A.M. et al. (2002) Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan NPs. Pharmaceutical Research (24):1415-1426, 2007.
  66. 66. Bhumkar, D.R. et al. (2007) Chitosan reduced gold NPs as novel carriers for transmucosal delivery of insulin. Pharmaceutical Research (24):1415-1426, 2007.
  67. 67. Jain, A.K. et al. (2008) Effective insulin delivery using starch NPs as a potential transnasal mucoadhesive carrier. European Journal of Pharmaceutics and Biopharmaceutics (69):426-435, 2008.
  68. 68. Henkin RI., Inhaled insulin-Intrapulmonary, intranasal and other routes of administration: Mechanisms of action, Nutrition (26):33-39, 2010.
  69. 69. Liu J., Gong T., Fu H., Wang C., Wang X., Chen Q., Zhang Q., He Q., Zhang Z.: Solid Lipid NPs for pulmonary delivery of insulin, International Journal of Pharmaceutics, (356):333-344, 2008.
  70. 70. Zhang Q., Shen Z., Nagai T., Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate NPs after pulmonary administration to normal rats, International Journal of Pharmaceutics, (218):75-80, 2001.
  71. 71. Huang Y.Y., Wang C.H., Pulmonary delivery of insulin by liposomal carriers, Journal of Control Release (113):9-14, 2006.
  72. 72. Garcia-Contreras L., Morçöl T., Bell S.J.D., Hickey A.J., Evaluation of novel particles as pulmonary delivery systems for insulin in rats, AAPS PharmSciTech (5): (Article 9), 2003.
  73. 73. Kawashima Y., Yamamoto H., Takeuchi H., Fujioka S., Hino T., Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. Journal of Control Release (62):279-287, 1999.
  74. 74. Mitra R., Pezron I., Li Y., Mitra A.K., Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids, International Journal of Pharmaceutics (217):25-31, 2001.
  75. 75. Sharma JPK., Bansal S., Banik A., Noninvasive routes of proteins and peptids drug delivery, Indian Journal of Pharmaceutical Sciences, 73(4):367-375, 2011.
  76. 76. Palermo A., Napoli N., Manfrini S., Lauria A., Strollo R., Pozzili P., Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study, Diabetes, Obesity and Metabolism, 13:42-46, 2011.
  77. 77. Palermo A., Maddaloni E., Pozzili P., Buccal Spray Insulin (Oralgen) for type 2 diabetes:what evidence? Expert Opinion on Biological Therapy 12(6):767-772, 2012.
  78. 78. Heinemann L., Jacques Y., Oral Insulin and Buccal Insulin, Journal of Diabetes Science and Technology, 3(3):568-584, 2009.
  79. 79. Starokadomskyy P.L., Dubey IY., New absorption promoter for the buccal delivery: preparation and characterization of lysalbinic acid, International Journal of Pharmaceutics (308):149-154, 2006.
  80. 80. Lee Y.C., Yalkowsky S.H., Effect of formulation on the systemic absorption of insulin from enhancer-free ocular devices, International Journal of Pharmaceutics (185):199-204, 1999.
  81. 81. YamamotoA., Luo A.M., Dodda-Kashi S., Lee V.H., The ocular route for systemic insulin delivery in the albino rabbit, Journal of Pharmacology and Experimental Therapeutics (249):249-255, 1989.
  82. 82. Pillion D.J., Atchison J.A., Wang R.X., Meezan E., Alkylglycosides enhance systemic absorption of insulin applied topically to the rat eye, Journal of Pharmacology and Experimental Therapeutics (271):1274-1280, 1994.
  83. 83. Ahsan F., Arnold J.J., Meezan E., Pillion D.J., Sucrose cocoate, a component of cosmetic preparations, enhances nasal and ocular peptide absorption, International Journal of Pharmaceutics (251):195-203, 2004.
  84. 84. Adikwu M.U., Evaluation of snail mucin motifs as rectal absorption enhancer for insulin in non-diabetic rat models, Biological and Pharmaceutical Bulletin (28):1801-1804, 2005.
  85. 85. Hosny E., Al-Shora H.I., Elmazar M.M, Relative hypoglycemic effect of insulin suppositories in diabetic beagle dogs: optimization of various concentrations of sodium salicylate and polyoxyethylene-9-lauryl ether, Biological and Pharmaceutical Bulletin (24):1294-1297, 2001.

Written By

Hatice Kübra Elçioğlu and Ali Demir Sezer

Submitted: 25 March 2014 Published: 25 July 2014